Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Peg-IFN-α-2b for chronic hepatitis B with hepatitis D virus coinfection
ChiCTR2400083914Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xinjiang Medical University
- Start
- Oct 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) and hepatitis D (HDV) (2 arms), sponsored by First Affiliated Hospital of Xinjiang Medical University. Primary endpoints: HBsAg clearance rate, HBsAg seroconversion rate and 1 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)hepatitis D (HDV)
Beyond the preview
Go deeper on ChiCTR2400083914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083914.